Evogene Ltd. Files 20-F, Details 2024 Financials & Stock Split

Ticker: EVGN · Form: 20-F · Filed: Mar 27, 2025 · CIK: 1574565

Sentiment: neutral

Topics: 20-F, annual-report, stock-split, financials

TL;DR

Evogene 20-F filed: 2024 financials out, 1:10 reverse stock split effective July 25, 2024.

AI Summary

Evogene Ltd. filed its 20-F annual report for the fiscal year ending December 31, 2024. The company, incorporated in L3 and headquartered in Rehovot, Israel, operates in the agriculture chemicals sector. The filing details financial adjustments, including a 1:10 reverse stock split effective July 25, 2024, which retroactively adjusted share counts and par value. Specific grant amounts from EU Horizon were also noted.

Why It Matters

This filing provides investors with a comprehensive overview of Evogene's financial performance and significant corporate actions like the recent stock split, crucial for understanding the company's current standing and future outlook.

Risk Assessment

Risk Level: medium — The filing indicates potential anti-dilutive effects from options and RSUs, and retroactive adjustments to share data, suggesting complexity in financial reporting and share structure.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Evogene Ltd. as indicated in the filing?

Evogene Ltd. is primarily involved in AGRICULTURE CHEMICALS, with a Standard Industrial Classification code of [2870].

When was the reverse stock split effective and what was its ratio?

The reverse stock split was effective on July 25, 2024, at a ratio of 1-for-10.

What impact did the reverse stock split have on the company's share data?

The reverse stock split retroactively adjusted the number of shares and par value, and also affected the weighted number of shares for prior years.

Are there any specific grants mentioned in the filing?

Yes, EU Horizon grant amounts received in May 2023 and August 2024 are excluded from certain reported figures.

What is the business address of Evogene Ltd.?

The business address is 13 Gad Feinstein Street, Park Rehovot, Rehovot, L3, 7638517.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on March 27, 2025 regarding Evogene Ltd. (EVGN).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing